An RCT finds the weekly GLP-1 agonist PEG-Loxe produces large dose-dependent weight loss in super-obese patients with type 2 diabetes. PICO summary and expert commentary.
Browsing: Type 2 Diabetes
Landmark trials and recent evidence on type 2 diabetes management, glucose-lowering therapy, and outcomes.
An ex-vivo study finds early empagliflozin dampens NLRP3 inflammasome activity in macrophages from post-MI diabetic patients, a mechanistic signal. PICO summary and commentary.
A small exploratory study finds combining empagliflozin with linagliptin shifts urinary microbiota toward a healthy pattern in type 2 diabetes, while empagliflozin alone raises some uropathogens; infection rates were not measured. PICO summary and commentary.
A GRADE substudy finds adults adding a second drug to metformin maintain high medication adherence over 3 years with small between-drug differences, while lower adherence robustly predicts worse glycaemic control. PICO summary and commentary.
An RCT finds adding oral agents to short-term intensive insulin improves early glucose control and beta-cell measures in new type 2 diabetes, but does not improve 12-month remission rates. PICO summary and commentary.
An RCT finds adding a 2-3 week course of intravenous alprostadil to standard care improves the clinical response rate and lipids in diabetic foot or neuropathy, though the trial was unblinded. PICO summary and commentary.
A cost-minimization analysis finds physician-led medication reviews reduce drug count and inappropriate prescriptions in psychiatric outpatients with diabetes while being cost-neutral. PICO summary and commentary.
Summary: In patients with type 2 diabetes experiencing cognitive decline, dapagliflozin and liraglutide treatment significantly improved neuroprotective outcomes compared to…
Summary: In older adults with type 2 diabetes (T2D) and mild cognitive impairment (MCI), hyperbaric oxygen therapy (HBOT) did not…
An observational ACCORD analysis finds higher weight-adjusted waist index is independently associated with more cardiovascular events, heart failure, and mortality in type 2 diabetes, outperforming BMI. PICO summary and commentary.